Clinical trial
A Phase II, Dose Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of Combretastatin A4 Phosphate for Treating Subfoveal Choroidal Neovascularization in Subjects With Pathologic Myopia
NCT01423149 is registered in ClinicalTrials.gov with Mateon Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Dose Ranging, Multi-Center Study to Evaluate the Safety and Efficacy of Combretastatin A4 Phosphate for Treating Subfoveal Choroidal Neovascularization in Subjects With Pathologic Myopia
- Lead sponsor
- Mateon Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2005
- Completion date
- January 31, 2007
- Enrollment
- 23 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.